Eli Lilly Issues Warning , About Fake Weight-Loss Drugs.<br />On June 20, Eli Lilly published an open letter, <br />warning about fake and compounded versions <br />of Mounjaro and Zepbound, ABC News reports. .<br />Lilly is committed to making life better <br />for people living with diabetes and <br />obesity through developing medicines <br />that change the way healthcare <br />providers can treat these diseases, Eli Lilly, via open letter.<br />Lilly Stands Against the Use of its <br />Medicines for Cosmetic Weight Loss, Eli Lilly, via open letter.<br />The company went on to advise consumers to stay away from buying weight-loss drugs online without a prescription. .<br />Lilly is deeply concerned about <br />the proliferation of online sales <br />and posts on social media involving <br />counterfeit, fake, compounded, <br />and any other unsafe or untested <br />versions of what they say is tirzepatide, Eli Lilly, via open letter.<br />Any products marketed simply as <br />“tirzepatide” (as opposed to <br />Mounjaro® and Zepbound®) were <br />not made by, studied by, or sold by <br />Lilly and are not FDA-approved. , Eli Lilly, via open letter.<br />Be aware that when you purchase <br />products that are not FDA-approved <br />medicines or obtain medicines from <br />an unverified source or without a prescription <br />from a licensed healthcare provider, <br />you may be purchasing fake, counterfeit, <br />or otherwise unsafe products. , Eli Lilly, via open letter.<br />Eli Lilly also addressed concerns about compounded medications.<br />Although compounding is legal amid <br />drug shortages, the FDA has shared <br />concerns about substandard products. .<br />Eli Lilly says that it has tested some compounded versions of its products, <br />only to find safety and efficacy issues.<br />Some products had high bacteria counts <br />and impurities, while others were <br />entirely different chemical structures.
